Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

“The Pink Sheet” DAILY – Most Notable Stories Of 2012

Jan 02 2013

• By Denise Peterson

Related Content

Beyond Bapi: Alzheimer’s Pipeline Runs Deep

Aug 13 2012

Oral Dosing May Not Be Enough To Win Speedy Adoption Of Pfizer’s RA Pill <em>Xeljanz</em>

Nov 12 2012

Biosimilar Meeting Requests Increase, But FDA Cancels Some For Lack Of Data

Dec 12 2012

Post-Lipitor Pfizer Will Have Two Business Models: Innovation And Value

Jan 31 2012

FDA Wants To Help You Develop Drugs

Dec 06 2012

FDA Biosimilars Guidances Address Immunogenicity Studies, European Bridge Data, Analytics

Feb 09 2012

GSK To Downplay Europe Because of Poor Innovation Support, Focuses On U.S. and Japan Instead

Feb 07 2012

Roche Shakes Up R&D, Closes Nutley Operations

Jun 26 2012

Drug Shortages Mostly FDA’s Fault, House Oversight Committee Concludes

Jun 15 2012

Bapineuzumab Failure Raises More Doubts About Beta Amyloid Approach In Alzheimer’s

Jul 24 2012

GSK’s DoJ Settlement Requires Execs To Forfeit Bonuses If Misconduct Occurs

Jul 02 2012

PDUFA V: Review Model Evaluators Will Observe All FDA-Sponsor Meetings

Jul 05 2012

How Far Can Big Pharma Collaboration Go? Much Further, Executives Say

Sep 29 2012

Related Companies

Roche Holding AG

Genentech, Inc.

Pfizer Inc.

Johnson & Johnson

GSK plc

Bristol Myers Squibb Company

AstraZeneca PLC

IQVIA Holdings Inc.

More from Archive

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window